Target intelligence / Profile preview

Nitrilase 1 (NIT1)

Target
NIT1
Molecular classification
Enzyme, Amidase (specifically deaminated glutathione amidase), Member of the nitrilase protein family (nitrilase superfamily)
01

Overview

Nitrilase 1 (NIT1) is an enzyme belonging to the nitrilase protein family, best characterized as a deaminated glutathione amidase or metabolite repair enzyme. NIT1 hydrolyzes deaminated glutathione (dGSH), a potentially harmful metabolite produced as a side product of transaminase activity, thereby preventing its accumulation and contributing to cellular detoxification and maintenance of glutathione homeostasis. NIT1 is highly conserved across eukaryotes, localizes to both mitochondria and cytosol, and is implicated in tumor suppression through interactions with proteins such as Fhit and the TGFβ–Smad2/3 signaling pathway. Reduced expression of NIT1 is associated with more aggressive tumor properties in colorectal cancer; however, its role in cancer can be context-dependent, influencing both tumor growth and chemosensitivity in different tissues. No drugs are currently known to target NIT1 directly, and no significant toxicities are linked to its modulation, though its deficiency leads to unique metabolic perturbations.

Other names
Deaminated glutathione amidasedGSH amidaseNitrilase homolog 1
02

Mechanism of action

Hydrolysis of deaminated glutathione (dGSH), a damaging side-product of transaminase activity, to prevent accumulation and cellular toxicity. Potential interaction with tumor suppressor pathways (via physical interaction with Fhit protein and recruitment of Smad2/3 to TGFβ receptors).

03

Biological functions

Metabolite repair (removal of damaged/aberrant metabolites, specifically deaminated glutathione)Regulation of cell growthTumor suppressionInduction of cell cycle arrest and apoptosis (via TGFβ–Smad2/3 signaling)
04

Disease associations

Cancer (tumor suppression, especially in colorectal carcinoma; context-dependent roles in lung cancer)Other (potential roles from accumulating metabolites in knockout models, but no dramatic phenotype)
05

Safety considerations

None specific reported; NIT1 knockout in mice and cells does not result in dramatic phenotype, though loss can increase cell proliferation and stress resistanceContext-dependent effects on tumorigenesis (loss can decrease tumor volume and increase chemosensitivity in some lung cancer models, but reduce differentiation in other cancers)
06

Biomarkers

NIT1 expression (downregulation is associated with poor differentiation and invasiveness in colorectal carcinoma)dGSH accumulation (in NIT1-deficient states)

Beyond the preview

Go deeper on Nitrilase 1 (NIT1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nitrilase 1 (NIT1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call